Table II.
Overview of clinical parameters and their influence on overall survival.
| Clinical parameter | Variables, n (%) | Influence on OS (P-value) |
|---|---|---|
| Age at diagnosis, years | 0.566 | |
| <60 | 11 (47.83%) | |
| >60 | 12 (52.17%) | |
| Median age, years | 59.96 | |
| Age range, years | 47.36-80.82 | |
| Sex | 0.927 | |
| Female | 12 (52.17%) | |
| Male | 11 (47.83%) | |
| EGFR status | 0.437 | |
| EGRF normal | 11 (52.17%) | |
| EGFR amplified | 12 (47.83%) | |
| IDH1/2 status | ND | |
| Wild-type | 22 (95.65%) | |
| Mutated | 1 (4.35%) | |
| Tmz | 0.158 | |
| Yes | 15 (65.2%) | |
| No | 7 (30.4 %) | |
| Unknown: | 1 (4.35%) | |
| Radiotherapy | ND | |
| Yes | 22 (95.65%) | |
| Unknown | 1 (4.35%) | |
| Type of surgery | 0.001 | |
| Gross-total | 19 (82.6%) | |
| Subtotal | 4 (17.4%) |
OS, overall survival; ND, not determined; TMZ, temozolomid; IDH1/2 status, mutation status of IDH1 and IDH2 genes.